Les résultats et les conclusions des travaux menés par l’écosystème Experts Recherche Lymphome sont publiés dans des journaux médicaux de premier plan.
Lysa
2023_LYSA_Randomized Phase III Trial Evaluating Sub-Cutaneous Rituximab for the First Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study
J Clin Oncol . 2023 Apr 18;JCO2202327. doi: 10.1200/JCO.22.02327.
En savoir plus
Lysa
2022_LYSA_Employment situation among long-term Hodgkin lymphoma survivors in Europe: an analysis of patients from nine consecutive EORTC-LYSA trials
DOI: 10.1007/s11764-022-01305-w
En savoir plus
Lysa
2023_LYSA_High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network
DOI: 10.1200/JCO.22.01780
En savoir plus
Lysa
2023_LYSA_Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome
DOI: 10.3324/haematol.2022.281226
En savoir plus
Lysa
2023_LYSA_Central nervous system relapse in younger patients with diffuse large B-cell lymphoma – a LYSA and GLA/ DSHNHL analysis
doi: 10.1182/bloodadvances.2022008888.
En savoir plus
Lysa
2022_LYSA_From Stem Cell Transplantation to CAR-T Therapy in Relapse-Refractory Diffuse Large B-Cell Lymphoma
doi.org/10.18103/mra.v10i8.3014
En savoir plus
Lysa
2022_LYSA_Do we have to exclude all relapsed diffuse large B-cell lymphoma patients not in complete remission from autologous stem cell transplant?
doi: 10.1111/bjh.18468
En savoir plus
Lysa
2022_LYSA_Outcomes of patients with aggressive B-Cell lymphoma after failure of anti-CD19 CAR T-Cell Therapy. A DESCAR-T analysis
doi: 10.1182/blood.2022016945.
En savoir plus
Calym
HemSys_Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase
Leukemia & Lymphoma, 59:12, 2812-2820, DOI: 10.1080/10428194.2018.1441408
En savoir plus
Calym
HemSys_IGHV segment utilization in immunoglobulin gene rearrangement differentiates patients with anti-myelin-associated glycoprotein neuropathy from others immunoglobulin M-gammopathies
Haematologica 2018;103(5):e207-e210; https://doi.org/10.3324/haematol.2017.177444.
En savoir plus
Calym
HemSys_Diagnostic value of 18-F fluorodeoxyglucose PET/CT and bone scan in Schnitzler syndrome
Autoimmunity, 52:7-8, 264-271, DOI: 10.1080/08916934.2019.1680649
En savoir plus
Calym
HemSys_Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO)
Br J Haematol, 179: 439-448. https://doi.org/10.1111/bjh.14881
En savoir plus
HemSys_Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study
Oncotarget. 2016; 7: 85573-85583. Retrieved from https://www.oncotarget.com/article/10764/text/
En savoir plus
Calym
HemSys_Switches of tyrosine-kinase inhibitors in chronic phase of chronic myeloid leukemia in real life
Am J Hematol, 93: E329-E331. https://doi.org/10.1002/ajh.25217
En savoir plus
Calym
HemSys_Impact of High-Dose Methotrexate on the Outcome of Patients with Diffuse Large B-Cell Lymphoma and Skeletal Involvement
Cancers 2021, 13(12), 2945; https://doi.org/10.3390/cancers13122945
En savoir plus
Calym
HemSys_Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network
Neuro-Oncology, Volume 18, Issue 9, September 2016, Pages 1297–1303, https://doi.org/10.1093/neuonc/now033
En savoir plus
Calym
HemSys_Management and prognosis of 66 patients with B-cell non-Hodgkin lymphoma presenting with initial spinal cord compression: a French retrospective multicenter study
Leukemia & Lymphoma, 56:7, 2025-2031, DOI: 10.3109/10428194.2014.977884
En savoir plus
Lysa
2022_LYSA_A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
doi: 10.1038/s41591-022-01969-y.
En savoir plus
Lysa
2022_LYSA_PET-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T-cells
doi: 10.3324/haematol.2021.280550.
En savoir plus
Lysa
2022_LYSA_Interpretation of 2-[ 18 F]FDG PET/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors
Eur Radiol . 2022 Sep;32(9):6536-6544.
En savoir plus
Lysa
2022_LYSA_Nodal cytotoxic peripheral T-cell lymphoma occurs frequently in the clinical setting of immunodysregulation and is associated with recurrent epigenetic alterations
Mod Pathol . 2022 Aug;35(8):1126-1136.
En savoir plus
Lysa
2022_LYSA_Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5-year analysis of the French early access program (EPA)
Br J Haematol . 2022 Jul;198(1):203-206.
En savoir plus
Lysa
2022_LYSA_Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study
Haematologica . 2022 Jul 1;107(7):1681-1686.
En savoir plus
Lysa
2022_LYSA_Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with Mantle Cell lymphoma, a LYSA retrospective study
Bone Marrow Transplant . 2022 Apr;57(4):627-632.
En savoir plus